# SenesTech Inc. (SNES)

**Exchange:** NASDAQ  
**Sector:** Basic Materials  
**Market cap:** $6M  
**Price:** $1.71 (-0.87%)

> SenesTech Inc. is a biotechnology company specializing in the development and commercialization of fertility control technologies for humane management of animal pest populations, particularly rodents. Its primary products include ContraPest, a liquid bait with active ingredients 4-vinylcyclohexene diepoxide and triptolide that serves as the only U.S. EPA-registered contraceptive for both male and female rats, and Evolve, a soft bait featuring cottonseed oil that limits reproduction in rats from the first breeding cycles after consumption. The company also offers Evolve Mouse, an adapted version targeting male and female mice after one to two breeding cycles. These products integrate into comprehensive integrated pest management programs, providing non-lethal alternatives to traditional rodenticides for urban, commercial, warehousing, and municipal applications. SenesTech Inc. supports global distribution efforts, including partnerships in regions like Indonesia, New Zealand, Belize, and Australia, alongside direct-to-consumer e-commerce channels such as Amazon. Additionally, it provides teleconsulting and technical advisory services to optimize pest control strategies. Founded in 2004 and headquartered in Phoenix, Arizona, SenesTech Inc. focuses on sustainable, environmentally friendly solutions for pest management across residential, business, and public sectors.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2M | $1M | -$7M | -$6M | — |
| 2024 | $2M | $1M | -$6M | -$6M | — |
| 2023 | $1M | $539,000 | -$8M | -$8M | — |
| 2022 | $1M | $464,000 | -$10M | -$10M | — |
| 2021 | $600,000 | $244,000 | -$9M | -$8M | — |
| 2020 | $282,000 | $1,000 | -$8M | -$8M | — |
| 2019 | $143,000 | $42,000 | -$10M | -$10M | — |
| 2018 | $297,000 | $56,000 | -$12M | -$12M | — |
| 2017 | $52,000 | $7,000 | -$12M | -$12M | — |
| 2016 | $318,000 | $318,000 | -$11M | -$11M | — |
| 2015 | $241,000 | — | -$16M | -$18M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $13M | $3M | $10M | $8M | — |
| 2024 | $3M | $767,000 | $3M | $1M | — |
| 2023 | $7M | $942,000 | $6M | $5M | — |
| 2022 | $7M | $2M | $5M | $5M | — |
| 2021 | $12M | $1M | $10M | $9M | — |
| 2020 | $6M | $2M | $4M | $4M | $673,000 |
| 2019 | $5M | $2M | $3M | $2M | $137,000 |
| 2018 | $8M | $1M | $6M | $5M | $261,000 |
| 2017 | $9M | $2M | $8M | $2M | $591,000 |
| 2016 | $13M | $2M | $11M | $12M | $183,000 |
| 2015 | $941,000 | $5M | -$11M | $141,000 | $477,000 |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$6M | $138,000 | -$6M |
| 2024 | -$6M | $84,000 | -$6M |
| 2023 | -$8M | $149,000 | -$8M |
| 2022 | -$9M | $174,000 | -$9M |
| 2021 | -$8M | $100,000 | -$8M |
| 2020 | -$7M | $114,000 | -$7M |
| 2019 | -$8M | $71,000 | -$8M |
| 2018 | -$9M | $239,000 | -$9M |
| 2017 | -$9M | $898,000 | -$10M |
| 2016 | -$7M | $57,000 | -$7M |
| 2015 | -$4M | $130,000 | -$4M |

Source: [CompaniesByCap](https://companiesbycap.com/company/SNES)